Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy

BACKGROUND: Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a prognostic factor in partial responder/non-responder groups remains uncertain. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ács, Balázs, Zámbó, Veronika, Vízkeleti, Laura, Szász, A. Marcell, Madaras, Lilla, Szentmártoni, Gyöngyvér, Tőkés, Tímea, Molnár, Béla Á., Molnár, István Artúr, Vári-Kakas, Stefan, Kulka, Janina, Tőkés, Anna-Mária
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320658/
https://www.ncbi.nlm.nih.gov/pubmed/28222768
http://dx.doi.org/10.1186/s13000-017-0608-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320658/
https://www.ncbi.nlm.nih.gov/pubmed/28222768
http://dx.doi.org/10.1186/s13000-017-0608-5

Ejemplares similares